Guidelines for the treatment of hepatitis C virus infection in injection drug users: Status quo in the European Union countries

被引:37
作者
Reimer, J
Schulte, B
Castells, X
Schafer, I
Polywka, S
Hedrich, D
Wiessing, L
Haasen, C
Backmund, M
Krausz, M
机构
[1] Univ Hamburg, Ctr Interdisciplinary Addict Res, D-20246 Hamburg, Germany
[2] Gen Hosp Munich Schwabing, Munich, Germany
[3] Hosp Univ Vall Hebron, Dept Psychiat, Barcelona, Spain
[4] European Monitoring Ctr Drugs & Drug Addict, Lisbon, Portugal
关键词
D O I
10.1086/427456
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Treatment guidelines are considered to be an important tool in steering patients to medical treatment. This study was conducted to analyze guidelines for the treatment of hepatitis C virus (HCV) infection in injection drug users (IDUs) in the European Union (EU) countries as a component of treatment access. National and international databases, expert contacts, professional societies, and health administrations were approached to acquire guidelines. According to their quality standard, guidelines were divided into expert opinions, semiofficial guidelines, official guidelines, and consensus processes. Recommendations for the treatment of HCV infection in IDUs vary substantially, from lack of recommendations and outright treatment disapproval to recommendations for treatment under specified circumstances. Recent guidelines that apply qualified process procedures that include literature research tend to be more permissive. Qualified guideline processes in each EU country and subsequently renewed pan-European guidelines are needed.
引用
收藏
页码:S373 / S378
页数:6
相关论文
共 47 条
[31]  
Lucidarme D, 2002, GASTROEN CLIN BIOL, V26, pB112
[32]   Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial [J].
Manns, MP ;
McHutchison, JG ;
Gordon, SC ;
Rustgi, VK ;
Shiffman, M ;
Reindollar, R ;
Goodman, ZD ;
Koury, K ;
Ling, MH ;
Albrecht, JK .
LANCET, 2001, 358 (9286) :958-965
[33]   Seroprevalence of hepatitis C markers among intravenous drug users in western European countries:: a systematic review [J].
Matheï, C ;
Buntinx, F ;
Damme, PV .
JOURNAL OF VIRAL HEPATITIS, 2002, 9 (03) :157-173
[34]  
Michielsen P, 2003, ACTA GASTRO-ENT BELG, V66, P15
[35]   Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b [J].
Neri, S ;
Bruno, CM ;
Abate, G ;
Ierna, D ;
Mauceri, B ;
Cilio, D ;
Bordonaro, F ;
Pulvirenti, D ;
Italiano, C ;
Caruso, L .
CLINICAL THERAPEUTICS, 2002, 24 (10) :1627-1635
[36]  
*NICE, 2000, NICE GUID US RIB INT
[37]  
PEREZ JS, 2001, GUIAS CLIN, V1, P53
[38]  
Postma MJ, 2001, UN B NARCOTICS, V53, P79
[39]  
Robaeys G, 2002, ACTA GASTRO-ENT BELG, V65, P99
[40]   Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups [J].
Schaefer, M ;
Schmidt, F ;
Folwaczny, C ;
Lorenz, R ;
Martin, G ;
Schindlbeck, N ;
Heldwein, W ;
Soyka, M ;
Grunze, H ;
Koenig, A ;
Loeschke, K .
HEPATOLOGY, 2003, 37 (02) :443-451